Advertisement
Advertisement
Madrigal Pharmaceuticals, Inc. (MDGL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 288.25 |
| Open | 289.80 |
| Bid | 285.00 x 1200 |
| Ask | 292.40 x 1000 |
| Day's Range | 282.63 - 292.41 |
| 52 Week Range | 57.15 - 315.45 |
| Volume | |
| Avg. Volume | 624,298 |
| Market Cap | 5.158B |
| Beta (5Y Monthly) | -0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.65 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 303.00 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for MDGL
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Madrigal Pharmaceuticals, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic MoatyesterdayMorningstar
- Simply Wall St.
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit
With the business potentially at an important milestone, we thought we'd take a closer look at Madrigal...
- Zacks
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
- Zacks
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
